|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 708.50 INR | +0.14% |
|
-0.38% | -16.27% |
| Mar. 06 | Alembic Pharmaceuticals Makes First Prescription Sale of Pivya in US | MT |
| Feb. 26 | Alembic Pharmaceuticals Gets Final Nod from US FDA for Lamotrigine Orally Disintegrating Tablets | MT |
| Capitalization | 139B 1.52B 1.31B 1.18B 1.13B 2.06B 2.16B 13.94B 5.59B 66.78B 5.69B 5.57B 239B | P/E ratio 2026 * |
21.4x | P/E ratio 2027 * | 16.4x |
|---|---|---|---|---|---|
| Enterprise value | 146B 1.59B 1.37B 1.23B 1.18B 2.16B 2.26B 14.59B 5.84B 69.87B 5.95B 5.82B 250B | EV / Sales 2026 * |
1.96x | EV / Sales 2027 * | 1.71x |
| Free-Float |
29.24% | Yield 2026 * |
1.62% | Yield 2027 * | 1.93% |
Last Transcript: Alembic Pharmaceuticals Limited
| 1 day | +0.14% | ||
| 1 week | -0.38% | ||
| Current month | -0.38% | ||
| 1 month | -11.18% | ||
| 3 months | -21.26% | ||
| 6 months | -25.15% | ||
| Current year | -16.27% |
| 1 week | 690 |  | 724.5 |
| 1 month | 690 | | 811.8 |
| Current year | 690 | | 847.95 |
| 1 year | 690 | | 1,107.9 |
| 3 years | 462.3 | | 1,303.9 |
| 5 years | 462.3 | | 1,303.9 |
| 10 years | 414.4 | | 1,303.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 78 | 2012-06-07 | |
G Krishnan
DFI | Director of Finance/CFO | - | 2025-07-06 |
Manisha Saraf
CMP | Compliance Officer | - | 2023-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 78 | 2012-06-07 | |
| Director/Board Member | 50 | 2006-12-31 | |
| Director/Board Member | 66 | 2003-01-17 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.14% | -0.38% | -12.68% | +34.76% | 1.52B | |
| +0.72% | -5.86% | +8.50% | +210.49% | 885B | |
| +0.32% | -3.23% | +44.97% | +54.54% | 579B | |
| -0.96% | -0.85% | +9.19% | +48.19% | 407B | |
| -2.93% | -7.03% | +12.72% | +26.04% | 350B | |
| -1.25% | -5.55% | +23.92% | +55.59% | 302B | |
| -1.85% | -6.70% | +20.55% | +34.98% | 301B | |
| -0.24% | -6.49% | +23.18% | +4.22% | 286B | |
| +0.53% | -4.80% | +16.27% | +57.17% | 199B | |
| -0.83% | -3.37% | +24.03% | +77.45% | 179B | |
| Average | -0.64% | -4.26% | +17.06% | +60.34% | 349.02B | |
| Weighted average by Cap. | -0.47% | -4.59% | +19.86% | +86.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 74.18B 807M 696M 628M 603M 1.1B 1.15B 7.43B 2.98B 35.57B 3.03B 2.96B 127B | 82.23B 895M 771M 696M 668M 1.22B 1.28B 8.23B 3.3B 39.43B 3.36B 3.29B 141B |
| Net income | 6.57B 71.44M 61.6M 55.61M 53.36M 97.29M 102M 657M 263M 3.15B 268M 262M 11.26B | 8.4B 91.36M 78.77M 71.11M 68.23M 124M 130M 841M 337M 4.03B 343M 336M 14.4B |
| Net Debt | 6.43B 70.01M 60.36M 54.49M 52.28M 95.34M 99.78M 644M 258M 3.09B 263M 257M 11.03B | 1.75B 19.08M 16.45M 14.85M 14.25M 25.98M 27.19M 176M 70.33M 841M 71.61M 70.08M 3.01B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-03-06 | 708.50 ₹ | +0.14% | 62,638 |
| 26-03-05 | 707.50 ₹ | +1.32% | 43,101 |
| 26-03-04 | 698.30 ₹ | -0.99% | 59,557 |
| 26-03-02 | 705.25 ₹ | -0.84% | 58,524 |
| 26-02-27 | 711.20 ₹ | -2.52% | 114,860 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- APLLTD Stock
Select your edition
All financial news and data tailored to specific country editions
